RASSF1 antibody, zgc:92505 antibody, wu:fc17f02 antibody, zgc:112224 antibody, 123F2 antibody, NORE2A antibody, RASSF1A antibody, RDA32 antibody, REH3P21 antibody, AA536941 antibody, AU044980 antibody, Rassf1A antibody, Rassf1B antibody, Rassf1C antibody, NPR2-like, GATOR1 complex subunit antibody, Ras association (RalGDS/AF-6) domain family 1 antibody, Ras association domain family member 1 antibody, putative rassf1 antibody, Ras association domain family member 1 L homeolog antibody, Ras association (RalGDS/AF-6) domain family member 1 antibody, NPRL2 antibody, rassf1 antibody, RASSF1 antibody, Smp_157340 antibody, rassf1.L antibody, Rassf1 antibody
Background
The tumor suppressor gene RASSF1A (3p21.3), human Ras association domain family 1A, is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, small intestine, colon, and peripheral blood leukocytes. RASSF1A expression is inhibited by hypermethylation of the CpG island including the promoter and early transcribed regions of the human RASSF1A gene. Hypermethylated RASSF1A promoter is observed in primary tumors. Furthermore, RASSF1A is related with cell cycle regulation, apoptosis and microtubule stability.